Treatment of psoriasis and psoriatic arthritis

BioDrugs

Volumn 27, Issue SUPPL. 1, 2013, Pages 3-12

  Papoutsaki, Marina ^a   Costanzo, Antonio ^b  

^a ANDREAS SYGROS HOSPITAL   (Greece)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; APILIMOD; BRIAKINUMAB; BRODALUMAB; CALCIPOTRIOL; COAL TAR; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DITHRANOL; EFALIZUMAB; EMOLLIENT AGENT; ETANERCEPT; ETRETIN; GOLIMUMAB; INFLIXIMAB; INFLUENZA VACCINE; IXEKIZUMAB; KERATOLYTIC AGENT; LIVE VACCINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PSORALEN; SECUKINUMAB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

ABORTION; BIOLOGICAL THERAPY; BONE MARROW SUPPRESSION; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CYTOKINE RELEASE; DEMYELINATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECCHYMOSIS; FATIGUE; HEADACHE; HEART DEATH; HEART INFARCTION; HEPATITIS B; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; LIVER TOXICITY; LYMPHOMA; NON MELANOMA SKIN CANCER; PATHOGENESIS; PHOTOTHERAPY; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SPERMATOZOON COUNT; TUBERCULOSIS; ULTRAVIOLET B RADIATION; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, PSORIATIC; DERMATOLOGIC AGENTS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; METHOTREXATE; MOLECULAR TARGETED THERAPY; PSORIASIS; RECOMBINANT FUSION PROTEINS;

EID: 84892707974     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/BF03325637     Document Type: Review

References (64)

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58 (5): 826-50.
2. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370 (9583): 263-71.
3. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332 (9): 581-8.
4. Gelfand JM, Feldman SR, Stern RS, et al. Determinants of quality of life in patients with psoriasis: A study from the US population. JAmAcad Dermatol 2004; 51 (5): 704-8.
5. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41 (3 Pt 1): 401-7.
6. Stankler L. The effect of psoriasis on the sufferer. Clin Exp Dermatol 1981; 6 (3): 303-6.
7. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 2010; 34 (3): J314-21.
8. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64 Suppl 2: II18-23; discussion II4-5.
9. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008; 58 (5): 851-64.
10. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann RheumDis 2005; 64 Suppl. 2: Ii14-7.
11. Roberson ED, Bowcock AM. Psoriasis genetics: breaking the barrier. Trends in genetics: TIG 2010; 26 (9): 415-23.
12. Bowes J, Barton A. The genetics of psoriatic arthritis: lessons from genomewide association studies. Discov Med 2010; 10 (52): 177-83.
13. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361 (5): 496-509.
14. Fitch E, Harper E, Skorcheva I, et al. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007; 9 (6): 461-7.
15. Nograles KE, Davidovici B, Krueger JG. New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 2010; 29 (1): 3-9.
16. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006; 27 (1): 17-23.
17. Liu H, Rohowsky-Kochan C. Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol 2008; 180 (12): 7948-57.
18. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445 (7130): 866-73.
19. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007; 449 (7162): 564-9.
20. Ganguly D, Chamilos G, Lande R, et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. J Exp Med 2009; 206 (9): 1983-94.
21. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- And RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111 (6): 821-31.
22. Tzu J, Kerdel F. From conventional to cutting edge: The new era of biologics in treatment of psoriasis. Dermatol Ther 2008; 21 (2): 131-41.
23. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: metaanalysis of randomized controlled trials. Br J Dermatol 2008; 159 (3): 513-26.
24. Brimhall AK, King LN, Licciardone JC, et al. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: A meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159 (2): 274-85.
25. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60 (4): 976-86.
26. EMEA. European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab). [Online] 2009; Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2009/11/ WC500014516.pdf.
27. FDA. FDA Statement on the Voluntary Withdrawal of Raptiva From the U.S. Market. [Online] 2009; Available from: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2009/ucm149561.htm.
28. Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 2008; 58 (1): 94-105.
29. Astellas PharmaUSInc.AMEVIVE- (alefacept) Prescribing Information. Revised May 2011. [Online]; Available from: http://www.astellas.us/docs/amevive. pdf.
30. Krueger GG, Papp KA, Stough DB, et al. A randomized, double-blind, placebo- controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002; 47 (6): 821-33.
31. Lebwohl M, Christophers E, Langley R, et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139 (6): 719-27.
32. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58 (1): 106-15.
33. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158 (3): 558-66.
34. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349 (21): 2014-22.
35. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152 (6): 1304-12.
36. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56 (1): 31 e1-15.
37. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: A phase III, multicentre, doubleblind trial. Lancet 2005; 366 (9494): 1367-74.
38. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371 (9625): 1665-74.
39. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371 (9625): 1675-84.
40. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362 (2): 118-28.
41. Krueger GG. Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2003; 17 Suppl 2:17-24.
42. Abbott Laboratories. HUMIRA- (adalimumab). Prescribing information. [Online]; Available from: http://www.rxabbott.com/pdf/humira.pdf.
43. Amgen/Pfizer. Enbrel- (etanercept). Prescribing information. [Online]; Available from: http://pi.amgen.com/united-states/enbrel/derm/enbrel-pi.pdf.
44. Pariser DM, Leonardi CL, Gordon K, et al. Integrated safety analysis: Shortand long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol 2011. Oct 18 (Epub ahead of print) http://dx.doi.org/10.1016/j. jaad.2011.07.040.
45. Electronic Medicines Compendium. Remicade 100 mg powder for concentrate for solution for infusion. Summary of Product Characteristics. Schering- Plough Ltd. [Online] 2010; Available from: http://www.medicines.org.uk/emc/document. aspx?documentId=3236.
46. Centocor Ortho Biotech Inc. Remicade(RM) (infliximab) for IV injection. [Online] 2009; Available from: http://www.remicade.com/remicade/assets/HCP-PPI. pdf.
47. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003; 62 (7): 686-7.
48. European Medicines Agency. Stelara European public assessment report. [Online]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/000958/human-med-001065.jsp&mid= WC0b01ac058001d125&murl=menus/medicines/medicines.jsp&jsenabled=true.
49. Centocor Ortho Biotech Inc. STELARA- (ustekinumab). Prescribing Information. [Online]; Available from: http://www.medversation.com/medversation/ assets/PI-MedGuides/STELARA-PI.pdf.
50. Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011; 164 (4): 862-72.
51. Kyle S, Chandler D, Griffiths CE, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) 2005; 44 (3): 390-7.
52. Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: A systematic review and economic evaluation. Health technology assessment 2006; 10 (31): Iii-iiv, xiii-xvi, 1-239.
53. Partsch G, Steiner G, Leeb BF, et al. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997; 24 (3): 518-23.
54. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52 (10): 3279-89.
55. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007; 34 (5): 1040-50.
56. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50 (7): 2264-72.
57. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005; 52 (4): 1227-36.
58. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64 (8): 1150-7.
59. Sharp JT, Young DY, Bluhm GB, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985; 28 (12): 1326-35.
60. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007; 56 (2): 476-88.
61. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009; 68 (5): 702-9.
62. Centocor Ortho Biotech Inc. SIMPONI- (golimumab). Prescribing Information. [Online]; Available from: https://www.simponi.com/sites/default/ files/pdf/prescribing-information.pdf.
63. Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol 2011; 12 (2): 113-25.
64. Traczewski P, Rudnicka L. Briakinumab for the Treatment of Plaque Psoriasis. BioDrugs 2012; 26 (1): 9-20.